|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5980 EUR | -2.29% |
|
-13.71% | -61.07% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 56.03M | |
| 64.91x | 6.09x | -0.89x | 5.24x | 19.49x | 26.09x | 2.66% | 315B | |
| 23.13x | 1.93x | -13.08x | 3.18x | 11.34x | 18.71x | 1.72% | 67.81B | |
| 11.66x | 12.23x | 0.07x | 5.9x | 9.07x | 9.82x | - | 9.23B | |
| 17.18x | 1.49x | 0.83x | 2.19x | 7.5x | 8.97x | 2.59% | 8.56B | |
| 21.18x | 5.63x | 2.12x | 6x | 16.95x | 17.72x | -.--% | 4.18B | |
| 30.97x | - | 0.2x | 5.9x | 16.86x | 27.31x | - | 3.59B | |
| 39.31x | 2.34x | -1.28x | 2.22x | 27.39x | 41.35x | 0.79% | 3.55B | |
| 107.96x | - | -0.65x | - | - | - | -.--% | 2.79B | |
| 58.57x | - | -0.11x | - | - | - | - | 1.16B | |
| 17.33x | 0.76x | -0.63x | 1.36x | 24.3x | 41.6x | 4.08% | 1.06B | |
| -67x | 1.63x | 1.01x | - | - | - | - | 900M | |
| Average | 29.56x | 4.01x | -1.13x | 4.00x | 16.61x | 23.95x | 1.69% | 34.82B | |
| Weighted average by Cap. | 54.89x | 5.38x | -2.77x | 4.83x | 17.70x | 24.26x | 2.44% |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
